Inflammation-homing “living Drug Depot” for Efficient Arthritis Treatment

Chenglan Feng,Lihua Pan,Xianyan Qin,Daming Li,Tao Chen,Zhicong Lin,Guojiao Li,Qin Wang

DOI: https://doi.org/10.1016/j.actbio.2022.07.013

IF: 10.633

2022-01-01

Acta Biomaterialia

Abstract:Delivering therapeutic agents efficiently to inflamed joints remains an intractable problem in rheumatoid arthritis (RA) treatment due to the complicated physiological barriers. Circulating monocytes could selec-tively migrate to inflamed sites and differentiate into resident macrophages to aggravate RA. Therefore, a drug carrier that can be specifically internalized by circulating monocytes and switch monocytes into anti-inflammatory phenotype when reaching inflamed sites, might bypass the in vivo physiological barri-ers and achieve efficient RA therapy. Herein, we design a dextran sulfate (DS) functionalized nanoparti-cle (ZDNP) to selectively deliver anti-inflammatory agent dexamethasone (Dex) to circulating monocytes via the scavenger receptors on monocytes. Monocytes engulfing drug-loaded ZDNP could subsequently home to arthritic joints and act as a "living drug depot" to combat RA. Results revealed that ZDNP could be preferentially internalized by circulating monocytes when intravenously administrated in vivo . In a rat arthritic model, we found that circulating monocytes remarkably facilitated drug distribution and re-tention in inflamed joints. Moreover, monocytes engulfing drug-loaded nanoparticles exhibited favorable anti-inflammatory ability and M2-biased differentiation. Our work offers a facile approach to achieve site -directed anti-inflammatory therapy by taking advantage of the inflammation-homing ability of circulating monocytes.Statement of significanceCirculating monocytes can migrate to inflamed sites and then differentiate into macrophages to aggra-vate arthritis. Therefore, a drug carrier that can be specifically internalized by circulating monocytes and switch monocytes into anti-inflammatory phenotype when reaching inflamed sites may achieve efficient arthritis therapy. Here, we designed a monocyte-targeting nanoparticle (ZDNP) to selectively deliver anti-inflammatory Dex to circulating monocytes. When injected intravenously, ZDNP was effectively internal-ized by circulating monocytes via a scavenger receptor and subsequently was transported to arthritic joints, where monocytes engulfing the drug-loaded nanoparticles could switch to an anti-inflammatory phenotype to inhibit arthritis progress. We provide detailed evidence about the in vivo fate of ZDNP and unravel how monocytes act as a "living drug depot" to achieve site-directed arthritis therapy.(c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.